Nedosiran (DCR-PHXC)
Primary Hyperoxaluria (Types 1, 2, 3)
Key Facts
Indication
Primary Hyperoxaluria (Types 1, 2, 3)
Phase
Phase 3
Status
Completed/Acquired
Company
About Dicerna Pharmaceuticals
Dicerna Pharmaceuticals established itself as a leader in next-generation RNAi therapeutics through its proprietary, liver-targeted GalXC™ and GalXC-Plus™ technology platforms. The company advanced a promising pipeline, most notably nedosiran for primary hyperoxaluria, and forged significant partnerships with industry leaders like Novo Nordisk, Roche, and Eli Lilly. Its successful trajectory culminated in a strategic acquisition by Novo Nordisk in December 2021, integrating Dicerna's platform to expand the acquirer's capabilities in genetic medicine for cardiometabolic and rare diseases.
View full company profile